Clinical trial · Observational
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Fibrolamellar Carcinoma | Fibrolamellar Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatic Angiosarcomas | — | UNRESOLVED | — |
| Hepatic Carcinosarcomas | — | UNRESOLVED | — |
| Hepatic Cystadenoma | — | UNRESOLVED | — |
| Hepatic Epithelioid Hemangioendothelioma | Liver Epithelioid Hemangioendothelioma | ALIAS | 0.90 |
| Hepatic Leiomyosarcomas | — | UNRESOLVED | — |
| Hepatic Neuroendocrine Carcinoma | Liver Neuroendocrine Carcinoma | ALIAS | 0.90 |
| Hepatoblastoma | Hepatoblastoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocholangiocarcinoma |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
- timeFrame
- up to 5 years from the date of diagnosis
- description
- Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
Secondary outcomes (3)
- measure
- Recurrence-free survival (for non-metastatic patients)
- timeFrame
- up to 5 years from diagnosis
- description
- Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news
- measure
- Progression-free survival (for metastatic patients)
- timeFrame
- up to 5 years from diagnosis
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older, * with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma * diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort * for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies. Exclusion Criteria: * without social security * No access to tumor block
References
Publications (0)
Data not yet available